Vanguard Group Inc. Has $84.04 Million Holdings in Xencor, Inc. $XNCR

Key Points

• Vanguard Group Inc. has reduced its stake in Xencor, Inc. by 1.5%, owning a total of 7,898,466 shares worth approximately $84 million after selling 118,900 shares in the first quarter.
• Recent analyst reports have led to significant target price adjustments for Xencor, with estimates ranging from $6.00 to $27.00, reflecting mixed sentiments on the stock.
• Xencor reported earnings per share of ($0.41), outperforming estimates by $0.37, with revenue growth of 82.4% year-over-year, highlighting strong performance despite overall losses.

Vanguard Group Inc. lowered its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,898,466 shares of the biopharmaceutical company's stock after selling 118,900 shares during the quarter. Vanguard Group Inc. owned about 11.10% of Xencor worth $84,040,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of XNCR. LPL Financial LLC increased its holdings in Xencor by 12.0% in the 4th quarter. LPL Financial LLC now owns 19,680 shares of the biopharmaceutical company's stock valued at $452,000 after buying an additional 2,113 shares during the period. Wells Fargo & Company MN increased its holdings in Xencor by 50.7% in the 4th quarter. Wells Fargo & Company MN now owns 36,086 shares of the biopharmaceutical company's stock valued at $829,000 after buying an additional 12,144 shares during the period. Raymond James Financial Inc. bought a new stake in Xencor in the 4th quarter valued at $2,329,000. Sterling Capital Management LLC increased its holdings in Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,040 shares during the period. Finally, CANADA LIFE ASSURANCE Co increased its holdings in Xencor by 11.0% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 83,535 shares of the biopharmaceutical company's stock valued at $1,918,000 after buying an additional 8,290 shares during the period.

Xencor Trading Up 1.0%

NASDAQ XNCR traded up $0.08 on Friday, hitting $8.13. 769,384 shares of the company were exchanged, compared to its average volume of 749,722. The firm has a 50 day moving average of $8.29 and a two-hundred day moving average of $9.91. The company has a market cap of $579.83 million, a P/E ratio of -3.39 and a beta of 0.89. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. During the same quarter in the prior year, the company earned ($1.07) EPS. The firm's quarterly revenue was up 82.4% on a year-over-year basis. Research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In other Xencor news, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. This represents a 13.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,194 shares of company stock worth $103,209. Company insiders own 4.76% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on XNCR. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a report on Thursday, May 8th. Wedbush lowered their price target on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Royal Bank Of Canada reduced their target price on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, August 21st. Finally, Wells Fargo & Company reduced their target price on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.71.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.